Dare Bioscience Inc (DARE)

[9HikeDiscGolf]

Brokers Release Average Price Target Of 5.00 On Cerulean Pharma Inc. (CERU)
By Warren Smith / in US Broker Ratings / on Wednesday, 15 Feb 2017 12:22 PM

According to the most recent research notes issued by analysts 3 analysts have outstanding research reports on Cerulean Pharma Inc. (CERU), whilst 1 of which rate the stock “Buy”, 0 “Outperform”, 0 “Underperform”, 0 “Sell”, while 2 “Hold”.

The latest updates which have been released by analysts/brokers for Cerulean Pharma Inc. (CERU) are outlined below.

10/19/2016 – Broker: Leerink Swann Rating: market perform New Target: 1.5 reiteration

10/19/2016 – Broker: Roth Capital Rating: buy New Target: 2.5 reiteration

08/30/2016 – Broker: Barclays Rating: overweight New Target: 2 reiteration

08/19/2016 – Broker: Canaccord Genuity Rating: buy New Target: 20 reiteration

08/18/2016 – Broker: JMP Securities Rating: market perform downgrade

08/18/2016 – Broker: Janney Montgomery Scott Rating: neutral New Target: 1 downgrade

08/18/2016 – Broker: Wedbush Rating: neutral New Target: 1 downgrade

05/20/2015 – Broker: Zacks Rating: buy New Target: 7 upgrade

The average target price given to the company from the latest broker reports is 5.00

The stock decreased -6.49% (-0.10) during the last days session, reaching 1.44 and roughly 3191089 shares were bought or sold by traders.

Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

http://www.ukmarketnews.co.uk/2017/02/15/brokers-release-average-price-target-of-5-00-on-cerulean-pharma-inc-ceru-3/